InspireMD, Inc. (II2.F)
- Previous Close
2.2000 - Open
2.2000 - Bid 2.2200 x --
- Ask 2.3600 x --
- Day's Range
2.2000 - 2.2000 - 52 Week Range
1.7800 - 3.4800 - Volume
1,035 - Avg. Volume
25 - Market Cap (intraday)
70.325M - Beta (5Y Monthly) 0.74
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6700 - Earnings Date May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard neuroprotection system for transcarotid access and neuro protection, as well as treating acute stroke with tandem lesions. It has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Miami, Florida.
www.inspiremd.comRecent News: II2.F
View MorePerformance Overview: II2.F
Trailing total returns as of 4/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: II2.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: II2.F
View MoreValuation Measures
Market Cap
70.05M
Enterprise Value
41.54M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
14.91
Price/Book (mrq)
2.12
Enterprise Value/Revenue
6.71
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-44.34%
Return on Equity (ttm)
-84.68%
Revenue (ttm)
7.01M
Net Income Avi to Common (ttm)
-32.01M
Diluted EPS (ttm)
-0.6700
Balance Sheet and Cash Flow
Total Cash (mrq)
34.64M
Total Debt/Equity (mrq)
6.48%
Levered Free Cash Flow (ttm)
-11M